Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, greater than 18 years old.~* Surgically confirmed diagnosis of malignant glioma, specifically anaplastic glioma (anaplastic astrocytoma \[AA\], anaplastic oligodendroglioma \[AO\], anaplastic oligoastrocytoma \[AOA\]) or glioblastoma multiforme (GBM).~* Must have completed at least 2 cycles (2 months) of conventional 5/28 temozolomide, with radiological evidence of progression.~* GBM treated with concurrent chemoradiation with temozolomide according to the EORTC/NCIC (European Organization for Research \& Treatment of Cancer/National Cancer Institute of Canada) protocol.~* Evidence of progression confirmed radiologically (CT \[computed tomography\] or MRI \[magnetic resonance imaging\]).~* Patients must be enrolled within 2 weeks of last radiological confirmation of progression, except for patients undergoing surgical resection.~* Patients undergoing surgical resection for recurrent disease must be enrolled within 2 weeks of the post-surgical scan.~* Patients with no residual disease after surgery are allowed.~* Steroids dose should have been stabilized during the last 2 weeks prior to enrollment.~* Use of medically approved contraception in fertile males and females.~* Women of childbearing potential must have a negative urine or serum pregnancy test (urinary excretion or serum level of bHCG \[beta human chorionic gonadotropin\]) within 24 hours of inclusion in the study.~* Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.~* Signed informed consent form.~Exclusion Criteria:~* GBM progression during the first 2 months of adjuvant temozolomide (5/28).~* AA progression during the first 2 months of standard temozolomide therapy (5/28).~* Chemotherapy for the malignant glioma other than temozolomide.~* More than one prior course of chemotherapy with temozolomide.~* Patient evolving from anaplastic glioma to GBM following primary therapy.~* Patient older than 70 years or who received no conventional chemoradiation regimen.~* Patient who received radiotherapy for recurrent disease.~* Patient with metastatic disease.~* Known human immunodeficiency virus (HIV) infection.~* History of non-compliance to other therapies.~* Inadequate hematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion):~* Absolute neutrophil count \<=1.5 ×10\^9/L;~* Platelets \<=100 ×10\^9/L;~* Hemoglobin \<90 g/L;~* Serum creatinine \>=1.5 times upper limit of laboratory normal (ULN);~* Total serum bilirubin \>=1.5 times ULN;~* ASAT (AST \[aspartate aminotransferase\]) or ALAT (ALT \[alanine aminotransferase) \>2.0 times ULN;~* Alkaline phosphatase of \>2.5 times ULN.~* Known chronic hepatitis B or hepatitis C infection.~* Any other serious medical condition, according to the medical judgment of the physician prior to inclusion in the study.~* Any medical condition that could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction).~* Other malignancies during the previous 5 years with the exception of surgically cured carcinoma in-situ of the cervix and basal cell carcinoma or non-melanoma skin cancer.~* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule as discussed with the patient before inclusion in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): Temozolomide will be administered at a dose of 50 mg/m\^2 for cycles of 28 days for 12 months or until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).